Zacks: Analysts Anticipate IDEAYA Biosciences (NASDAQ:IDYA) Will Post Earnings of -$0.67 Per Share

Equities analysts predict that IDEAYA Biosciences (NASDAQ:IDYA) will post ($0.67) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for IDEAYA Biosciences’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.77). The company is scheduled to issue its next quarterly earnings report on Monday, November 11th.

On average, analysts expect that IDEAYA Biosciences will report full-year earnings of ($2.65) per share for the current fiscal year, with EPS estimates ranging from ($3.06) to ($1.75). For the next year, analysts expect that the company will post earnings of ($3.13) per share, with EPS estimates ranging from ($4.13) to ($2.01). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Monday, August 12th. The company reported ($1.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.66).

A number of brokerages recently weighed in on IDYA. Robert W. Baird began coverage on IDEAYA Biosciences in a research note on Monday, September 9th. They set an “outperform” rating and a $30.00 price objective for the company. Oppenheimer began coverage on IDEAYA Biosciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $17.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $19.20.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new position in IDEAYA Biosciences in the second quarter valued at about $49,000. BlackRock Inc. acquired a new position in IDEAYA Biosciences in the second quarter worth about $82,000. Laurion Capital Management LP acquired a new position in IDEAYA Biosciences in the second quarter worth about $199,000. Vanguard Group Inc. acquired a new position in IDEAYA Biosciences in the second quarter worth about $349,000. Finally, Monashee Investment Management LLC acquired a new position in IDEAYA Biosciences in the second quarter worth about $354,000. Hedge funds and other institutional investors own 25.12% of the company’s stock.

Shares of IDEAYA Biosciences stock opened at $5.79 on Friday. The company has a current ratio of 18.94, a quick ratio of 18.95 and a debt-to-equity ratio of 0.05. IDEAYA Biosciences has a 12-month low of $4.89 and a 12-month high of $16.90. The stock has a 50-day moving average price of $7.05.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

See Also: What does a neutral rating on stocks mean?

Get a free copy of the Zacks research report on IDEAYA Biosciences (IDYA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.